Literature DB >> 27533371

Prophylactic Left Internal Mammary Artery Graft In Mildly-Stenosed Coronary Lesions. Still an Open Discussion.

Levent Cerit1.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27533371      PMCID: PMC4976962          DOI: 10.5935/abc.20160105

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


× No keyword cloud information.
I have read the article entitled "Prophylactic Left Internal Mammary Artery Graft in Mildly-Stenosed Coronary Lesions. Still An Open Discussion" by Evora et al.1 with great interest, recently published in Arquivos Brasileiros de Cardiologia. The investigators reported that the idea of a prophylactic left internal mammary artery (LIMA) on left anterior descending in mild-stenosed vessels is not confirmed yet by clinical evidence.[1] Berger at al.[2] reported that all moderate coronary lesions should be LIMA grafted during primary coronary bypass surgery. Coronary angiography, anyhow quantitative, remains a relatively weak tool to determine the functional repercussion of a stenosis. Thus, it is likely that some lesions with a diameter stenosis < 50% were actually hemodynamically significant and, on the contrary, that stenoses with a diameter stenosis > 50% were not. Fractional flow reserve (FFR) is a guide wire-based index derived from intracoronary pressure measurements that has been shown to evaluate the functional significance of a coronary stenosis much more accurately than angiography.[3] FFR has been shown to be a predictable surrogate for noninvasive stress testing and is thus a useful tool in determining the suitability of revascularization.[4] In the light of these knowledges, FFR might be a useful tool to evaluate moderate coronary lesions with regard to revascularization appropriateness. The author(s) letter is based mainly on the excellent study carried out by Berger et al.[1] who reported that all moderate coronary lesions should be left internal mammary artery (LIMA) grafted during primary coronary bypass surgery. Coronary angiography, anyhow quantitative, remains a relatively weak tool to determine the functional repercussion of a stenosis. In other words, the coronary angiography can underestimate the real degree of the artery obstruction. Fractional flow reserve might be a useful tool to evaluate moderate coronary lesions with regard to revascularization appropriateness. Thank you very much for adding the important lesson that the “prophylactic left internal mammary artery graft in mildly-stenosed coronary lesions”, implies in the development of better tools. The coronary flow quantification improvement would be associated with a more comfortable adoption of the Berger opinion that “all moderate coronary lesions should be LIMA grafted during primary coronary bypass surgery”. However, the discussion remains open.[2]
  4 in total

1.  Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial.

Authors:  G J Bech; B De Bruyne; N H Pijls; E D de Muinck; J C Hoorntje; J Escaned; P R Stella; E Boersma; J Bartunek; J J Koolen; W Wijns
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

2.  Long-term patency of internal mammary artery bypass grafts: relationship with preoperative severity of the native coronary artery stenosis.

Authors:  Alexandre Berger; Philip A MacCarthy; Uwe Siebert; Stéphane Carlier; William Wijns; Guy Heyndrickx; Jozef Bartunek; Hugo Vanermen; Bernard De Bruyne
Journal:  Circulation       Date:  2004-09-14       Impact factor: 29.690

3.  Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty.

Authors:  N H Pijls; J A van Son; R L Kirkeeide; B De Bruyne; K L Gould
Journal:  Circulation       Date:  1993-04       Impact factor: 29.690

4.  Prophylactic Left Internal Mammary Artery Graft In Mildly-Stenosed Coronary Lesions. Still An Open Discussion.

Authors:  Paulo Roberto B Evora; Livia Arcêncio; André Schmidt; Alfredo José Rodrigues
Journal:  Arq Bras Cardiol       Date:  2016-03       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.